Squarepoint
ACOR

Squarepoint’s Acorda Therapeutics ACOR Stock Holding History

Squarepoint’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,463
Closed -$235K – 3629
2021
Q2 		$235K Buy
+2,463
New +$215K ﹤0.01% 2703
2021
Q1 		– Sell
-508
Closed -$42K – 3777
2020
Q4 		$42K Sell
508
-987
-66% -$90.8K ﹤0.01% 2814
2020
Q3 		$92K Buy
1,495
+393
+36% +$29.6K ﹤0.01% 2304
2020
Q2 		$97K Buy
+1,102
New +$116K ﹤0.01% 2021
2020
Q1 		– Sell
-304
Closed -$74K – 2711
2019
Q4 		$74K Buy
+304
New +$76.7K ﹤0.01% 2372
2019
Q2 		– Sell
-1,765
Closed -$2.81M – 2752
2019
Q1 		$2.81M Buy
1,765
+837
+90% +$1.51M 0.03% 634
2018
Q4 		$1.73M Sell
928
-127
-12% -$276K 0.02% 725
2018
Q3 		$2.49M Buy
1,055
+958
+988% +$2.97M 0.03% 632
2018
Q2 		$333K Sell
97
-92
-49% -$282K ﹤0.01% 1340
2018
Q1 		$537K Buy
+189
New +$566K 0.01% 1066
2017
Q2 		– Sell
-307
Closed -$774K – 1881
2017
Q1 		$774K Sell
307
-11
-3% -$31.7K 0.02% 697
2016
Q4 		$717K Buy
+318
New +$756K 0.03% 640

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's ACOR Position: Q3 2021 in Review

Squarepoint sold out of Acorda Therapeutics (ACOR) in Q3 2021, closing a stake of 2,463 shares — an estimated $235K sold.

Squarepoint first reported a position in ACOR in Q4 2016 and held it in 12 quarters. The position peaked at $2.81M in Q1 2019. 32 funds tracked by Wall St. Rank hold ACOR as of Q3 2021.

  • Squarepoint reported no remaining Acorda Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 2,463 Acorda Therapeutics shares in Q3 2021, an estimated $235K.
  • Squarepoint first reported a position in Acorda Therapeutics in Q4 2016 and held it in 12 quarters.
  • Squarepoint's Acorda Therapeutics position peaked at $2.81M in Q1 2019.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.